TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00901875
Drug: Buprenorphine + naloxone (Suboxone)
Normalized name: buprenorphine / naloxone
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02908529
Drug: Combination product of Atomoxetine and Oxybutynin
Normalized name: atomoxetine Oral Product
DrugBank: Atomoxetine (DB00289)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combination product of Atomoxetine 80 mg and Oxybutynin 5 mg 2 hours before sleep
Study: NCT02774681
Drug: Palbociclib
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given PO
Study: NCT03053869
Drug: Benzodiazepine - limited use strategy
Normalized name: 1,2-Benzodiazepine
DrugBank: 1,2-Benzodiazepine (DB12537)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. No routine use of any intraoperative benzodiazepines.~2. Accepted benzodiazepine use in the case of seizure, alcohol withdrawal, or known benzodiazepine dependence.~3. Accepted benzodiazepine use in patients who are hemodynamically unstable and/or have cardiac anatomy that puts them at high risk of developing ischemia on induction of anesthesia.
Study: NCT03053869
Drug: Benzodiazepine - Ad libitum strategy
Normalized name: 1,3-dihydro-7-nitro-5-phenyl-2H-1,4-benzodiazepin-2-one
DrugBank: Nitrazepam (DB01595)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1. Administration of some benzodiazepine to most patients undergoing cardiac surgery.~2. Accepted lack of benzodiazepine use in patients who have contraindications to the administration of these medications (e.g. documented allergy).
Study: NCT02598856
Drug: Intravenous (IV) naloxone
DrugBank: Naloxone (DB01183)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered as 1 ml Naloxon B Braun 0.4 mg/ml (0.4 mg naloxone), in an intravenous cannula in the opposite arm of which the blood samples are drawn from. IV bolus will be given rapidly (in less than 5 seconds)
Study: NCT02598856
Drug: Intramuscular (IM) naloxone
DrugBank: Naloxone (DB01183)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naloxone administered as 2 ml Naloxon B Braun 0.4 mg/ml (0.8 mg naloxone) in a Braun Omnifix 2.5 ml syringe using a BD Microlance 3 21G (green) 0.8x40 mm needle in the deltoid muscle of the non-dominant arm
Study: NCT00519688
Drug: Thalidomide
Normalized name: Thalidomide
DrugBank: Thalidomide (DB01041)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 100 mg, BID
Study: NCT00519688
Drug: Tegafur/Uracil
Normalized name: Tegafur/uracil
DrugBank: Tegafur-uracil (DB09327)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 125 mg/m2, based on tegafur, BID
Study: NCT01808820
Drug: Imiquimod
Normalized name: Imiquimod
DrugBank: Imiquimod (DB00724)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 5% topical cream applied to vaccine site before and after administrations of DC vaccine or lysate
Study: NCT00960479
Drug: Ribavirin 200 mg Oral Capsule (Geneva Pharmaceutical, U.S.A.)
Normalized name: ribavirin 200 MG
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00960479
Drug: Rebetol 200 mg Oral Capsule (Schering Corporation, U.S.A.)
Normalized name: S-adenosylmethionine 200 MG
DrugBank: Ademetionine (DB00118)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01024387
Drug: AMG 479
Normalized name: AMG 108
DrugBank: AMG 108 (DB05545)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01321957
Drug: Oxaliplatin, 5FU/LV, Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: bevacizumab at a dose of 5 mg/kg iv over 30 to 90 min (day 1) oxaliplatin at a dose of 85 mg/m2 iv over two hours (day 1) I-LV at a dose of 200 mg/m2 iv over two hours (day 1) 5-FU at a dose of 3200 mg/ m2 iv over 48 hours (day 1-3)
Study: NCT01321957
Drug: 5FU/LV, Oxaliplatin, Bevacizumab, Irinotecan
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: bevacizumab at a dose of 5 mg/kg iv over 30 to 90 min (day 1) irinotecan at a dose of 165 mg/m2 iv over two hours (day 1) oxaliplatin at a dose of 85 mg/m2 iv over two hours (day 1) I-LV at a dose of 200 mg/m2 iv over two hours (day 1) 5-FU at a dose of 3200 mg/ m2 iv over 48 hours (day 1-3)
Study: NCT03030287
Drug: OMP-305B83
Normalized name: OMP-54F28
DrugBank: Ipafricept (DB15045)
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous (in the vein) infusion
Study: NCT01813565
Drug: Hyaluronic acid/chondroitin sulfate
Normalized name: hyaluronic acid/chondroitin sulfate/collagen II/amino acids 40 mg-80 mg-400 mg ORAL CAPSULE
DrugBank: Hyaluronic acid (DB08818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Additional Hyaluronic acid/chondroitin sulfate instillation to the bladder
Study: NCT03030287
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: administered intravenously
Study: NCT03330184
Drug: Berberine Hydrochloride group
Normalized name: berberine
DrugBank: Berberine (DB04115)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03330184
Drug: Bifidobacterium group
Normalized name: BIFIDOBACTERIUM
DrugBank: Bifidobacterium spp. (DB18530)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03330184
Drug: Berberine Hydrochloride and Bifidobacterium group
Normalized name: berberine
DrugBank: Berberine (DB04115)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00015951
Drug: cytarabine
Normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00015951
Drug: mitoxantrone hydrochloride
Normalized name: Mitoxantrone Hydrochloride
DrugBank: Mitoxantrone (DB01204)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT05731934
Drug: HX301
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Description: At starting dose of 40 mg, followed by 4 dose levels of 80 mg, 120 mg, 160 mg, and 200 mg
Study: NCT02623504
Drug: Carbamazepine
Normalized name: Carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200-1200 mg by mouth daily given in divided doses in the morning and the evening. Doses are titrated weekly in 200 mg increments based upon subject's response.
Study: NCT00279565
Drug: buprenorphine
Normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00279565
Drug: methadone
Normalized name: Methadone
DrugBank: Methadone (DB00333)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00279565
Drug: pegylated interferon alfa-2b plus ribavirin
Normalized name: Interferon Alfa-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT04331600
Drug: Chloroquine phosphate
Normalized name: Chloroquine Phosphate
DrugBank: Chloroquine (DB00608)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral chloroquine phosphate for 14 days
Study: NCT00619021
Drug: gemcitabine hydrochloride
Normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 4 dose levels designated by cohort; 600 mg/m\^2, 800 mg/m\^2, 1000 mg/m\^2, 1200 mg/m\^2
Study: NCT01263145
Drug: Akt Inhibitor MK2206
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT01263145
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT00804947
Drug: Intravenous busulfan and melphalan
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: BU is administered intravenously at a dose of 3.2 mg/kg over three hours once a day on days -5 to -3 (total dose 9.6 mg/kg), followed by MEL at a dose of 140 mg/m2 on day -2. After one day of rest, progenitor cells are infused on day 0.
Study: NCT01394926
Drug: Optison
Normalized name: Optison
DrugBank: Albumin human (DB00062)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optison is a sterile non-pyrogenic suspension of perflutren for IV administration.
Study: NCT04081272
Drug: Sodium Chromate Cr51
Normalized name: sodium chromate Cr51
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium Chromate Cr 51 will be used to perform a red blood cell recovered study 24 hours post-transfusion.
Study: NCT00226135
Drug: lithium or lamotrigine
DrugBank: Lamotrigine (DB00555)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01737294
Drug: Qutenza exposure
Normalized name: Qutenza
DrugBank: Capsaicin (DB06774)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cutaneous patch
Study: NCT01989611
Drug: emtricitabine / tenofovir 200/300 mg
DrugBank: Emtricitabine (DB00879)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fixed dose combination of emtricitabine / tenofovir 200/300 mg once daily orally during one year
Study: NCT00389155
Drug: Vinflunine
Normalized name: vinflunine
DrugBank: Vinflunine (DB11641)
Approvals — FDA: no, EMA: no, PMDA: no
Description: solution for injection, IV, vinflunine: 280/320 mg/m2 + gemcitabine: 1000 mg/m2, every 3 wks, variable duration
Study: NCT00927394
Drug: Aliskiren
Normalized name: Aliskiren
DrugBank: Aliskiren (DB09026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aliskiren 150 mg tablet
Study: NCT00389155
Drug: Gemcitabine
Normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: solution for injection, IV, placebo + gemcitabine, 1000 mg/m2, every 3 wks, variable duration
Study: NCT00927394
Drug: Valsartan
Normalized name: Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Valsartan 160 mg capsules
Study: NCT00927394
Drug: Placebo for Aliskiren
DrugBank: Aliskiren (DB09026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Placebo for Aliskiren 150 mg tablets
Study: NCT00606983
Drug: Tamsulosin
Normalized name: Tamsulosin
DrugBank: Tamsulosin (DB00706)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral administration of Tamsulosin
Study: NCT01189643
Drug: irinotecan, temozolomide, and bevacizumab incorporated into an existing schedule of high dose alkylator
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Two cycles of the investigational combination irinotecan, temozolomide and bevacizumab- will be given followed by conventional chemotherapy with a modified P6 approach and surgical local control. Completion of modified P6 chemotherapy will be followed by a second-look surgery.
Study: NCT04212013
Drug: Ibrutinib
Normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ibrutinib capsules (140 mg each) will be dosed at 560 mg once daily on a 28-day cycle on a continuous basis.
Study: NCT04212013
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Will receive rituximab: 375 mg/m\^2 on days 1, 8, 15 and 22 of cycle 1
Study: NCT04497987
Drug: Bamlanivimab
Normalized name: Bamlanivimab
DrugBank: Bamlanivimab (DB15718)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered IV.
Study: NCT03761069
Drug: PTC299
Normalized name: PTC299
DrugBank: PTC299 (DB05173)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTC299 will be administered per the treatment arm description
Study: NCT04497987
Drug: Etesevimab
Normalized name: Etesevimab
DrugBank: Etesevimab (DB15897)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered IV.
Study: NCT01282424
Drug: Idelalisib
Normalized name: Idelalisib
DrugBank: Idelalisib (DB09054)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Idelalisib 150 mg tablet administered orally twice daily
Study: NCT02812667
Drug: Nivolumab + Plinabulin
DrugBank: Plinabulin (DB05992)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00682019
Drug: Levitra (Vardenafil, BAY38-9456)
Normalized name: vardenafil Oral Tablet [Levitra]
DrugBank: Vardenafil (DB00862)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5mg, 10mg or 20mg taken 8 hours before sexual intercourse
Study: NCT03772054
Drug: Sevoflurane
Normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Inhalation anesthetic agent
Study: NCT03772054
Drug: Propofol
Normalized name: Propofol
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous anesthetic agent
Study: NCT00740623
Drug: Carisbamate
Normalized name: carisbamate
DrugBank: Carisbamate (DB12338)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg/day for 14 weeks
Study: NCT00740623
Drug: Carisbamate
Normalized name: carisbamate
DrugBank: Carisbamate (DB12338)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1,200 mg/day for 14 weeks
Study: NCT00491920
Drug: cholecalciferol (Vitamin D3)
Normalized name: cholecalciferol (vitamin D3)
DrugBank: Cholecalciferol (DB00169)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 000 Iu x2/week~+ calcium 500 mg/cholecalciferol 400 IU x2/d
Study: NCT00512096
Drug: Ifosfamide
Normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1200 mg/m\^2 By Vein Over 2 Hours on Days 1-3
Study: NCT00512096
Drug: Paclitaxel (Taxol)
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 175 mg/m\^2 By Vein Over 3 Hours on Day 1
Study: NCT00512096
Drug: Cisplatin
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 mg/m\^2 By Vein Over 2 Hours on Days 1-3
Study: NCT00676910
Drug: JNJ-26854165
Normalized name: JNJ-42847922
DrugBank: Seltorexant (DB14961)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04832945
Drug: Ivermectin 6 Mg Oral Tablet
Normalized name: ivermectin 6 mg oral tablet
DrugBank: Ivermectin (DB00602)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ivermectin weekly oral dose 0.2 mg/kg equivalent for 4 weeks
Study: NCT03211195
Drug: Sotagliflozin (SAR439954)
Normalized name: sotagliflozin
DrugBank: Sotagliflozin (DB12713)
Approvals — FDA: no, EMA: yes, PMDA: no
Description: Pharmaceutical form: tablet~Route of administration: oral
Study: NCT02510911
Drug: corn starch (250 mg approx.)
Normalized name: Corn Starch
DrugBank: Starch, corn (DB11599)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients after laparoscopic colectomy will receive 3 times daily capsules with 250 mg corn starch together with the meals.~First capsule will be taken on the evening of surgery if surgery was completed before 1 pm, otherwise the first capsule will be taken on the morning of the next day.~Treatment consists of 10 capsules and will be stopped after the first solid bowel movement.
Study: NCT02515201
Drug: Taurolidine
Normalized name: Taurolidine
DrugBank: Taurolidine (DB12473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: taurolidine in central catheter lumen
Study: NCT04065633
Drug: P3-Fast
Normalized name: Fast Freeze
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg (2 × 100 mg) PF-04965842 Phase 3 tablet formulation under fasted conditions
Study: NCT04065633
Drug: Comm-Fast
Normalized name: Fast Freeze
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg PF-04965842 commercial tablet formulation under fasted conditions
Study: NCT04065633
Drug: Vari-Fast
Normalized name: Fast Freeze
DrugBank: Camphor (DB01744)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200 mg PF-04965842 variant tablet formulation with slower dissolution under fasted conditions
Study: NCT02907749
Drug: Carvedilol
Normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients are treated with carvedilol only.
Study: NCT04489121
Drug: Omalizumab
Normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: For patients in the Omalizumab group, subcutaneous injections of Omalizumab based on the specific participant's weight and serum total IgE was performed 2 weeks prior the anticipated pollen season.
Study: NCT01186640
Drug: Fludarabine, Mitoxantrone, Cyclophosphamide and Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: I. First treatment phase: Chemoimmunotherapy A-FMC~Alemtuzumab:~Cycle 1+2:~10 mg s.c., days 1-3~Cycle 3+4:~CR: 10 mg s.c., days 1-3 PR/SD: 30 mg s.c., days 1-3 Fludarabine: 20 mg/m2 i.v., days 1-3 Mitoxantrone: 6 mg/m2 i.v., day 1 Cyclophosphamide: 200 mg/m2 i.v., days 1-3 Repeat day 29, maximum 4 cycles. II. Second treatment phase: Maintenance-treatment with 30mg Alemtuzumab s.c. The maintenance therapy will start one month after the Final Staging and will be administered monthly during the first six months plus once in month 10 and 13.
Study: NCT00927394
Drug: Placebo for Valsartan
DrugBank: Valsartan (DB00177)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Placebo for Valsartan 160 mg capsules
Study: NCT01186640
Drug: Alemtuzumab
Normalized name: Alemtuzumab
DrugBank: Alemtuzumab (DB00087)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: maintenance with Alemtuzumab following a induction with combined immunochemotherapy consisting of Fludarabine, cyclophosphamide, mitoxantrone and alemtuzumab
Study: NCT01218997
Drug: Medisorb naltrexone 380 mg
Normalized name: naltrexone 380 MG
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Administered via intramuscular (IM) injection once every 4 weeks for up to 1 year.
Study: NCT01218997
Drug: Oral naltrexone 50 mg
DrugBank: Naltrexone (DB00704)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablet taken orally once daily for up to 1 year
Study: NCT00958035
Drug: bimatoprost ophthalmic 0.03% solution
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Apply one drop of study medication along the upper eyelid margin once daily in the evening
Study: NCT01211808
Drug: BMS-914832
Normalized name: BMS dasatinib
DrugBank: Dasatinib (DB01254)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Tablets, Oral, 30 mg, once, 1 day
Study: NCT01203358
Drug: Survanta
Normalized name: Survanta
DrugBank: Beractant (DB06761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Infants received up to four intratracheal doses of the surfactant.
Study: NCT02203955
Drug: Maltodextrin
Normalized name: Maltodextrin
DrugBank: Maltodextrin (DB12583)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 chews (maltodextrin) daily for 12 months
Study: NCT02938273
Drug: avelumab
Normalized name: Avelumab
DrugBank: Avelumab (DB11945)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Avelumab10 mg/kg i.v. at day -7, 7, 21,35 + maintenance therapy i.e avelumab10 mg/kg i.v. every 2 weeks for 6 months
Study: NCT02938273
Drug: cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: loading dose 400 mg/m2 i.v. day -7, 250 mg/m2 i.v weekly wk 1-7
Study: NCT00413010
Drug: pregabalin
Normalized name: Pregabalin
DrugBank: Pregabalin (DB00230)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: pregabalin 150-600 mg/day flexibly dosed for the first 6 weeks and fixed dosed for the last 2 weeks of total 8 weeks of double blind study period, + concurrent GAD treatment from the open-label study period
Study: NCT04494724
Drug: Clazakizumab
Normalized name: Clazakizumab
DrugBank: Clazakizumab (DB12849)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion
Study: NCT01069289
Drug: Budesonide/formoterol (Symbicort Turbuhaler)
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2x160/4.5 microgram, inhalation, twice daily, 12 weeks
Study: NCT01069289
Drug: Formoterol (Oxis Turbuhaler)
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 2 X 4.5 microgram, inhalation, twice daily, 12 weeks
Study: NCT01211808
Drug: Diltiazem
Normalized name: Diltiazem
DrugBank: Diltiazem (DB00343)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tablets, Oral, 360 mg, once daily, 10 days
Study: NCT03091803
Drug: Gadobenate Dimeglumine
Normalized name: Gadobenate Dimeglumine
DrugBank: Meglumine (DB09415)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT04023617
Drug: Nivolumab
Normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nivolumab 300mg + docetaxel 75mg/m2 IV q3w Nivolumab 200mg IV q2w
Study: NCT03091803
Drug: Gadoterate Meglumine
Normalized name: Gadoterate meglumine
DrugBank: Gadoteric acid (DB09132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT01114100
Drug: sertraline
Normalized name: Sertraline
DrugBank: Sertraline (DB01104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: starting dose 25 mg for 1 week, the increasing to 50 mg, after each visit evaluation whether dosage has to be increased to maximally 150 mg
Study: NCT02634606
Drug: Gamma Delta Tocotrienols - Low Dose
DrugBank: Tocotrienol (DB12647)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg capsule containing 63 mg Gamma Delta Tocotrienols 2x/day for 12 weeks.
Study: NCT02634606
Drug: Gamma Delta Tocotrienols - High Dose
DrugBank: Tocotrienol (DB12647)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg capsule containing 127 mg Gamma Delta Tocotrienols 2x/day for 12 weeks.
Study: NCT02634606
Drug: Sugar Pill
Normalized name: Invert Sugar
DrugBank: Invert sugar (DB09344)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 mg Placebo capsule containing 50% medium chain triglycerides and 50% glycerin 2x/day for 12 weeks.
Study: NCT02663141
Drug: Losartan
Normalized name: Losartan
DrugBank: Losartan (DB00678)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02663141
Drug: Intravitreal bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT00019474
Drug: hydroxyurea
Normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01659255
Drug: Tirabrutinib
Normalized name: Tirabrutinib
DrugBank: Tirabrutinib (DB15227)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules administered orally
Study: NCT04221191
Drug: Dimethyl Fumarate
Normalized name: Dimethyl Fumarate
DrugBank: Dimethyl fumarate (DB08908)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DMF as prescribed as standard of care.
Study: NCT01360177
Drug: Tri-iodothyronine
DrugBank: Liothyronine (DB00279)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 75 ug/8hr x 4 weeks; oral
Study: NCT01360177
Drug: Tri-iodothyronine
DrugBank: Liothyronine (DB00279)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg/day x 2
Study: NCT00261508
Drug: risperidone
Normalized name: Risperidone
DrugBank: Risperidone (DB00734)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT00131651
Drug: ATN-161
Normalized name: ATN-161
DrugBank: ATN-161 (DB05491)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02092766
Drug: artesunate
Normalized name: Artesunate
DrugBank: Artesunate (DB09274)
Approvals — FDA: yes, EMA: yes, PMDA: no
Study: NCT02092766
Drug: quinine
Normalized name: Quinine
DrugBank: Quinine (DB00468)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00885781
Drug: lipid emulsion for TPN
Normalized name: propofol lipid emulsion
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1-2 g lipid emulsion /kgBW-day, for consecutive 5 days
Study: NCT00300365
Drug: Pioglitazone
Normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pioglitazone, initially 30 mg, then titrated to 45 mg/day
Study: NCT00300365
Drug: Niacin ER
Normalized name: Niacin ER
DrugBank: Niacin (DB00627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Niacin ER 2.0 g/day
Study: NCT00300365
Drug: Aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: asprin 325 mg/day